CLINICAL TRIALS PROFILE FOR SOJOURN

All Clinical Trials for Sojourn

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00714740 ↗	Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude	Completed	University of Zurich	Phase 4	2008-06-01	The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude
NCT00928655 ↗	Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude	Completed	University of Zurich	Phase 4	2009-06-01	The purpose of the study is to investigate the effect of nasal continuous positive airway pressure in combination with acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude.
NCT02143609 ↗	Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance	Completed	University of Zurich	Phase 4	2014-05-01	The purpose of this study is to investigate the effect of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance of patients with chronic obstructive lung disease.
NCT02143687 ↗	Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance	Completed	University of Zurich	Phase 4	2014-05-01	The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance of patients with pulmonary hypertension or with interstitial lung disease.
NCT02150616 ↗	Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep	Active, not recruiting	University of Zurich	Phase 4	2014-05-01	The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of patients with pulmonary hypertension or with interstitial lung disease.
NCT02973958 ↗	Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision	Completed	Alberta Children's Hospital	Phase 1	2017-02-01	Circumcision is the most common surgical procedure performed by Pediatric Urologists. Ketorolac has been shown to have an efficacy similar to morphine in multi-modal analgesic regimens without the commonly associated adverse effects. This study aims to see if giving ketorolac during the operation will result in better pain control. We hypothesize that ketorolac will result in pain control similar to morphine with a lower incidence of side effects such as nausea and vomiting.

Clinical Trial Conditions for Sojourn

Condition Name

Condition Name for Sojourn
Intervention	Trials
Precapillary Pulmonary Hypertension	2
Balanitis	2
Interstitial Lung Disease	2
Obstructive Sleep Apnea Syndrome	2

Condition MeSH

Condition MeSH for Sojourn
Intervention	Trials
Sleep Apnea, Obstructive	3
Sleep Apnea Syndromes	3
Lung Diseases	3
Syndrome	2

Clinical Trial Locations for Sojourn

Trials by Country

Trials by Country for Sojourn
Location	Trials
Switzerland	5
Canada	2
United States	1

Trials by US State

Trials by US State for Sojourn
Location	Trials
Georgia	1

Clinical Trial Progress for Sojourn

Clinical Trial Phase

Clinical Trial Phase for Sojourn
Clinical Trial Phase	Trials
Phase 4	6
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for Sojourn
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for Sojourn

Sponsor Name

Sponsor Name for Sojourn
Sponsor	Trials
University of Zurich	5
Alberta Children's Hospital	2
Emory University	1

Sponsor Type

Sponsor Type for Sojourn
Sponsor	Trials
Other	8

Sojourn (Sevoflurane): Clinical Trials, Market Analysis, and Projections

Introduction to Sojourn (Sevoflurane)

Sojourn, known generically as sevoflurane, is a widely used inhalation anesthetic indicated for the induction and maintenance of general anesthesia in both adult and pediatric patients. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Safety Profile

Clinical Studies Overview

Sevoflurane has been extensively studied in various clinical trials involving a large number of patients. In these trials, sevoflurane was administered to a total of 3185 patients, including adults and pediatric patients, undergoing different types of surgeries and medical procedures[4].

Adverse Events and Side Effects

Clinical trials have identified several adverse events associated with sevoflurane. These include mild and transient events such as nausea, vomiting, and headache. More serious adverse events, though rare, include seizures, particularly in children and young adults, and cardiac arrest. Post-marketing reports have also highlighted the risk of malignant hyperthermia and nephrotoxicity associated with the compound A produced during the metabolism of sevoflurane[1][4].

Comparative Studies

Sevoflurane has been compared to other anesthetics like propofol, isoflurane, and halothane in clinical studies. For instance, recovery times from sevoflurane anesthesia were found to be comparable to those of propofol, with sevoflurane showing slightly faster emergence times but similar times to respond to commands[4].

Market Analysis

Current Market Size and Growth

The U.S. general anesthesia drugs market, which includes sevoflurane, was estimated at USD 1.67 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 2.8% from 2024 to 2030, reaching USD 2.03 billion by 2030[2].

Market Segments and Competitors

The market is segmented by drug type, route of administration, end-use, and application. In 2023, the propofol segment dominated the market with a 25.4% share, but sevoflurane remains a significant player. Key companies in the market include Baxter International Inc., AstraZeneca, AbbVie Inc., and Pfizer[2].

End-Use and Application

Hospitals are the primary settings for the use of general anesthesia drugs, capturing a substantial revenue share of 67.2% in 2023. Sevoflurane is used across various applications, including heart surgeries, general surgery, and knee and hip replacements[2].

Projections and Future Outlook

Market Growth Drivers

The growth of the general anesthesia drugs market, including sevoflurane, is driven by several factors:

• Increasing Number of Surgical Procedures: The rising number of surgical procedures, such as the 26.2 million reported in the U.S. in 2022, drives the demand for effective general anesthesia drugs[2].
• Technological Advancements: Innovations in anesthesia delivery systems and formulations enhance patient safety and efficiency, contributing to market growth.
• Regulatory Updates: FDA approvals and guidelines ensure the safety and reliability of anesthetics like sevoflurane, maintaining their market position[2].

Competitive Landscape

Sevoflurane faces competition from other anesthetics like propofol, desflurane, and isoflurane. However, its established safety profile, ease of use, and widespread availability help it maintain a significant market share. Recent developments in propofol formulations and the cost-effectiveness of other anesthetics are key factors to consider in the competitive landscape[2][5].

Global Clinical Trials Impact

The global clinical trials market, which is projected to grow significantly due to the high prevalence of chronic diseases, indirectly influences the demand for general anesthesia drugs. While many clinical trials are conducted outside the U.S. and EU due to cost and regulatory factors, the overall increase in clinical trials globally can drive the development and use of new and existing anesthetics like sevoflurane[3].

Key Takeaways

• Clinical Trials: Sevoflurane has been extensively studied in clinical trials, showing a generally safe profile with some rare but serious adverse events.
• Market Size and Growth: The U.S. general anesthesia drugs market is projected to grow at a CAGR of 2.8% from 2024 to 2030.
• Market Segments: Hospitals dominate the end-use segment, and propofol currently leads the market, but sevoflurane remains a significant player.
• Future Outlook: The market growth is driven by increasing surgical procedures, technological advancements, and regulatory updates.

FAQs

What is Sojourn (Sevoflurane) used for?

Sojourn (sevoflurane) is used for the induction and maintenance of general anesthesia in adult and pediatric patients for both inpatient and outpatient surgeries[1].

What are the common side effects of Sojourn?

Common side effects include nausea, vomiting, and headache. More serious but rare side effects include seizures and cardiac arrest[1][4].

How does Sojourn compare to other anesthetics?

Sevoflurane has recovery times comparable to propofol and is known for its ease of use and established safety profile. However, it faces competition from other anesthetics like desflurane and isoflurane, which offer advantages such as quicker recovery and lower risk of nephrotoxicity[2][5].

What drives the growth of the general anesthesia drugs market?

The growth is driven by an increasing number of surgical procedures, technological advancements in anesthesia, regulatory updates, and shifts in healthcare practices[2].

Which segment dominates the general anesthesia drugs market?

The hospitals segment dominates the market, capturing a substantial revenue share of 67.2% in 2023[2].

Sources

1. RxList: Sojourn (Sevoflurane Injection): Side Effects, Uses, Dosage...
2. Grandview Research: U.S. General Anesthesia Drugs Market Size | Report, 2030
3. Fortune Business Insights: Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032]
4. Drugs.com: Sojourn Inhalant: Package Insert / Prescribing Information
5. GMI Insights: Inhalation Anesthesia Market 2019-2025 | Global Industry Share...